Last updated: 18 July 2019 at 4:30pm EST

Jeffrey Alan Orion Holdings... Net Worth




The estimated Net Worth of Jeffrey Alan Orion Holdings... is at least $8.71 Mille dollars as of 19 May 2014. Jeffrey Holdings owns over 2,500 units of Heat Biologics Inc stock worth over $8,711 and over the last 10 years Jeffrey sold HTBX stock worth over $0.

Jeffrey Holdings HTBX stock SEC Form 4 insiders trading

Jeffrey has made over 1 trades of the Heat Biologics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Jeffrey bought 2,500 units of HTBX stock worth $10,325 on 19 May 2014.

The largest trade Jeffrey's ever made was buying 2,500 units of Heat Biologics Inc stock on 19 May 2014 worth over $10,325. On average, Jeffrey trades about 2,500 units every 0 days since 2014. As of 19 May 2014 Jeffrey still owns at least 3,660 units of Heat Biologics Inc stock.

You can see the complete history of Jeffrey Holdings stock trades at the bottom of the page.



Insiders trading at Heat Biologics Inc

Over the last 11 years, insiders at Heat Biologics Inc have traded over $311,853 worth of Heat Biologics Inc stock and bought 1,805,692 units worth $1,373,576 . The most active insiders traders include Louis C Bock, Michael Kharitonov e John K A Prendergast. On average, Heat Biologics Inc executives and independent directors trade stock every 319 days with the average trade being worth of $582,988. The most recent stock trade was executed by John K A Prendergast on 14 May 2021, trading 35,000 units of HTBX stock currently worth $205,450.



What does Heat Biologics Inc do?

Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company's gp96 platform is designed to activate immune responses against cancer or infectious diseases. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, and a COVID-19 vaccine program in preclinical development. In addition, Heat Biologics is also developing a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.



Complete history of Jeffrey Holdings stock trades at Heat Biologics Inc

Persona
Trans.
Transazione
Prezzo totale
Jeffrey Alan Orion Holdings...
Chief Executive Officer
Acquistare $10,325
19 May 2014


Heat Biologics Inc executives and stock owners

Heat Biologics Inc executives and other stock owners filed with the SEC include: